Department of Pharmacology and Toxicology, Faculty of Pharmacy, Deraya University, El-Minia, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt.
Fundam Clin Pharmacol. 2022 Apr;36(2):286-295. doi: 10.1111/fcp.12718. Epub 2021 Aug 10.
Sepsis is an extensive life-threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression. Among global intensive care units, sepsis-induced acute kidney injury is reported with high mortality rate. The purpose of this study was to evaluate the protective effect of the renin angiotensin aldosterone system (RAAS) inhibition on sepsis outcomes. Cecal ligation and puncture (CLP) procedure was applied for sepsis induction. The experimental design constituted of five groups of rats: sham, CLP-nontreated and CLP-treated with ramipril (10 mg/kg, p.o.), losartan (20 mg/kg, i.p.) and spironolactone (25 mg/kg, p.o.). Twenty-four hours after surgery, rats were euthanized for blood and tissue samples, which were used for assessment of serum inflammatory markers, and oxidative stress parameters, as well as to kidney function parameters. The tissue samples were used for histological and caspase-3 assessment. A survival study was conducted using another set of animals. Our results showed that the different RAAS inhibitors showed protective effects evidenced by enhanced overall survival following sepsis (80% in ramipril and spironolactone-treated and 60% in losartan-treated vs. 10% in the septic group), in addition to improved renal function parameters and reduction of oxidative stress and inflammation. The timely use of RAAS inhibitors during sepsis might represent a new therapeutic approach in septic patient.
脓毒症是一种广泛的危及生命的疾病,是由于宿主的异常反应引起的,这种反应从最初的炎症和氧化应激风暴中持续扩展,并在免疫抑制的晚期结束。在全球重症监护病房中,报告的脓毒症引起的急性肾损伤具有高死亡率。本研究旨在评估肾素-血管紧张素-醛固酮系统(RAAS)抑制对脓毒症结局的保护作用。应用盲肠结扎和穿刺(CLP)程序诱导脓毒症。实验设计包括五组大鼠:假手术组、CLP 未治疗组和 CLP 治疗组,分别给予雷米普利(10mg/kg,口服)、氯沙坦(20mg/kg,腹腔注射)和螺内酯(25mg/kg,口服)。手术后 24 小时,处死大鼠取血和组织样本,用于评估血清炎症标志物和氧化应激参数以及肾功能参数。组织样本用于进行组织学和 caspase-3 评估。使用另一组动物进行了生存研究。我们的结果表明,不同的 RAAS 抑制剂具有保护作用,表现在脓毒症后的整体存活率提高(雷米普利和螺内酯治疗组为 80%,氯沙坦治疗组为 60%,而脓毒症组为 10%),此外还改善了肾功能参数,降低了氧化应激和炎症。在脓毒症期间及时使用 RAAS 抑制剂可能代表脓毒症患者的一种新的治疗方法。